MedTrace Logo

Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

NCT00536653 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 618

Last updated 2007-09-28

No results posted yet for this study

Summary

The aim of this study is to determine the long term effects of two types of hormonal treatment for advanced prostate cancer (LHRH agonists and the antiandrogen bicalutamide)on the bone mineral density of patients.

Conditions

Interventions

DRUG

Bicalutamide and Calcium/ Vitamin D supplementation

Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily

DRUG

LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation

3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily

DRUG

LHRH agonists (Goserelin acetate)

3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)

Sponsors & Collaborators

  • Wirral University Teaching Hospital NHS Trust

    lead OTHER

Principal Investigators

  • Nigel J Parr, MBBS, FRCS(Urol), MD · Wirral University Hospitals NHS Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Completion
2007-01-31

Countries

  • United Kingdom

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00536653 on ClinicalTrials.gov